{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:51:21Z","timestamp":1789775481863,"version":"4.0.1"},"reference-count":40,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pittsburgh Cure Sarcoma","award":["AWD00004925"],"award-info":[{"award-number":["AWD00004925"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Grade 2 and 3 and dedifferentiated chondrosarcomas (CS) are frequently associated with isocitrate dehydrogenase (IDH) mutations and often exhibit a poor clinical outcome. Treatment is limited mainly to surgery. Defining IDH status (wild type (WT) and mutant) and the associated transcriptome may prove useful in determining other therapeutic options in these neoplasms. Methods: Formalin-fixed paraffin-embedded material from 69 primary and recurrent grade 2, 3 and dedifferentiated CS was obtained. DNA sequencing for IDH1 and IDH2 mutations (n = 47) and RNA sequencing via Nextseq 2000 (n = 14) were performed. Differentially expressed genes (DEGs) were identified and used to predict aberrant biological pathways with Ingenuity Pathway Analysis (IPA) software (Qiagen). Gene Set Enrichment Analyses (GSEA) using subsets C3, C5 and C7 were performed. Differentially expressed genes were validated by immunohistochemistry. Outcome analysis was performed using the Wilcoxon test. Results: A set of 69 CS (28 females, 41 males), average age 65, distributed among femur, pelvis, humerus, and chest wall were identified from available clinical material. After further selection based on available IDH status, we evaluated 15 IDH WT and 32 IDH mutant tumors as part of this dataset. Out of 15 IDH WT tumors, 7 involved the chest wall\/scapula, while 1 of 32 mutants arose in the scapula. There were far more genes overexpressed in IDH WT tumors compared to IDH mutant tumors. Furthermore, IDH WT and IDH mutant tumors were transcriptomically distinct in the IPA and GSEA, with IDH mutant tumors showing increased activity in methylation pathways and endochondral ossification, while IDH WT tumors showed more activity in normal matrix development pathways. Validation immunohistochemistry demonstrated expression of WT1 and AR in IDH WT tumors, but not in IDH mutants. SATB2 was expressed in IDH mutant tumors and not in WT tumors. Outcome analysis revealed differences in overall survival between mutant and WT tumors (p = 0.04), dedifferentiated mutant and higher-grade (2, 3) mutant tumors (p = 0.03), and dedifferentiated mutant and higher-grade (2, 3) WT tumors (p = 0.03). The longest survival times were observed in patients with higher-grade WT tumors, while patients with dedifferentiated mutant tumors showed the lowest survival. Generally, patients with IDH WT tumors displayed longer survival in both the higher-grade and dedifferentiated groups. Conclusions: Grade 2, 3 and dedifferentiated chondrosarcomas are further characterized by IDH status, which in turn informs transcriptomic phenotype and overall survival. The transcriptome is distinct depending on IDH status, and implies different treatment targets.<\/jats:p>","DOI":"10.3390\/cancers16020247","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T05:12:17Z","timestamp":1704431537000},"page":"247","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Grade 2, 3 and Dedifferentiated Chondrosarcomas: A Comparative Study of Isocitrate Dehydrogenase-Mutant and Wild-Type Tumors with Implications for Prognosis and Therapy"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5398-8962","authenticated-orcid":false,"given":"Karen","family":"Schoedel","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5808-6770","authenticated-orcid":false,"given":"Tanya","family":"Heim","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA 15232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0168-4067","authenticated-orcid":false,"given":"Anette","family":"Duensing","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Lohse","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA 15232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Presutti","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Belayneh","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA 15232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumail","family":"Bhogal","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA 15232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Singh-Varma","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15206, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Chandran","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15206, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6171-0688","authenticated-orcid":false,"given":"Daniel","family":"Marker","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7921-8031","authenticated-orcid":false,"given":"Heather","family":"Szabo-Rogers","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Physiology and Pharmacology, College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3859-728X","authenticated-orcid":false,"given":"Kurt","family":"Weiss","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA 15232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"ref_1","unstructured":"WHO Classification of Tumours Editorial Board (2020). WHO Classification of Tumours Series, IARC. [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.jos.2021.07.024","article-title":"Prognostic impact of IDH mutations in chondrosarcoma","volume":"27","author":"Nakagawa","year":"2022","journal-title":"J. Orthop. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"772263","DOI":"10.3389\/fonc.2021.772263","article-title":"Metabolic pathways and targets in chondrosarcoma","volume":"11","author":"Micaily","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1002\/jbmr.4532","article-title":"Distinct roles of glutamine metabolism in benign and malignant cartilage tumors with IDH mutations","volume":"37","author":"Zhang","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13073-022-01084-0","article-title":"A genetic model for central chondrosarcoma evolution correlates with patient outcomes","volume":"14","author":"Cross","year":"2022","journal-title":"Genome Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Miwa, S., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., and Tsuchiya, H. (2022). Therapeutic targets and emerging treatments in advanced chondrosarcoma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031096"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-13-0083","article-title":"Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models and clinical opportunities","volume":"3","author":"Cairns","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1369\/00221554211062499","article-title":"IDH1\/2 mutations in cancer stem cells and their implications for differentiation therapy","volume":"70","author":"Molenaar","year":"2022","journal-title":"J. Histochem. Cytochem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/(SICI)1096-9896(199912)189:4<454::AID-PATH467>3.0.CO;2-N","article-title":"Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis","volume":"189","author":"Bovee","year":"1999","journal-title":"J. Pathol."},{"key":"ref_10","unstructured":"Nielsen, G., and Rosenberg, A. (2017). Diagnostic Pathology Bone, Elsevier. [2nd ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase 1 study of the mutant IDH1 inhibitor Ivosidenib: Safety and clinical activity in patients with advanced chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_12","unstructured":"National Comprehensive Cancer Network (2023). NCCN Clinical Practice Guidelines in Oncology, Bone Cancer, Version 1.2024, National Comprehensive Cancer Network."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1302\/0301-620X.82B1.0820055","article-title":"Experience in the treatment of dedifferentiated chondrosarcoma","volume":"82","author":"Mitchell","year":"2000","journal-title":"J. Bone Jt. Surg. Br."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: Role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cncr.30379","article-title":"Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor","volume":"123","author":"Schuetze","year":"2017","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/NEN.0b013e3181c391be","article-title":"Diagnostic use of IDH1\/2 mutation analysis in routine clinical testing of formalin fixed, paraffin embedded glioma tissues","volume":"68","author":"Horbinski","year":"2009","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41571-021-00521-0","article-title":"The implications of IDH mutations for cancer development and therapy","volume":"18","author":"Pirozzi","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/s41416-020-0814-x","article-title":"IDH mutation in glioma: Molecular mechanisms and potential therapeutic targets","volume":"122","author":"Han","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_20","unstructured":"WHO Classification of Tumours Editorial Board (2021). WHO Classification of Tumours Series, IARC. [5th ed.]."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"982424","DOI":"10.3389\/fphar.2022.982424","article-title":"Recent advances in IDH1 mutant inhibitor in cancer therapy","volume":"13","author":"Tian","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1038\/s41467-022-30453-x","article-title":"Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets","volume":"13","author":"Nacev","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/WCO.0b013e32834cd415","article-title":"Isocitrate dehydrogenase mutations in gliomas: Mechanisms, biomarkers and therapeutic target","volume":"24","author":"Guo","year":"2011","journal-title":"Curr. Opin. Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-019-12525-7","article-title":"Integrated molecular characterization of chondrosarcoma reveals critical determinants of disease progression","volume":"10","author":"Nicolle","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Venneker, S., Kruisselbrink, A., Baranski, Z., Palubeckaite, I., Briaire-de Bruijn, I., Oosting, J., French, P., Danen, E., and Bovee, J. (2020). Beyond the influence of IDH mutations: Exploring epigenetic vulnerabilities in chondrosarcoma. Cancers, 12.","DOI":"10.3390\/cancers12123589"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.14018","article-title":"Characterization of isocitrate dehydrogenase 1\/isocitrate dehydrogenase 2 gene mutation and the d-2-hydroxyglutarate oncometabolite level in dedifferentiated chondrosarcoma","volume":"76","author":"Mohammad","year":"2020","journal-title":"Histopathology"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Stoeckl, S., Lindner, G., Li, S., Schuster, P., Haferkamp, S., Wagner, F., Prodinger, P., Multhoff, G., Boxberg, M., and Hillman, A. (2020). SOX9 knockout induces polyploidy and changes sensitivity to tumor treatment strategies in a chondrosarcoma cell line. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207627"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"151704","DOI":"10.1016\/j.aanat.2021.151704","article-title":"Bone tissue and histological and molecular events during development of the long bones","volume":"235","author":"Blumer","year":"2021","journal-title":"Ann. Anat."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100271","DOI":"10.1016\/j.jbo.2019.100271","article-title":"The immune landscape of chondrosarcoma reveals an immunosuppressive environment in the dedifferentiated subtypes and exposes CSFR1 + macrophages as a promising therapeutic target","volume":"20","author":"Iseulys","year":"2020","journal-title":"J. Bone Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2353\/ajpath.2006.050001","article-title":"Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation","volume":"168","author":"Tiet","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/gcc.21974","article-title":"Genetic characterization of mesenchymal, clear cell and dedifferentiated chondrosarcoma","volume":"51","author":"Meijer","year":"2012","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5498","DOI":"10.3390\/cimb44110372","article-title":"The role of WRAP53 in cell homeostasis and carcinogenesis onset","volume":"44","author":"Gadelha","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","article-title":"Induction of pluripotent stem cells from adult human fibroblasts by defined factors","volume":"131","author":"Takahashi","year":"2007","journal-title":"Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1080\/15384101.2020.1762038","article-title":"Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients","volume":"19","author":"Liu","year":"2020","journal-title":"Cell Cycle"},{"key":"ref_36","first-page":"282","article-title":"Differential expression of the human insulin-like growth factor II gene. Characterization of the IGF-II mRNAs and an mRNA encoding a putative IGF-II associated protein","volume":"950","author":"Jansen","year":"1988","journal-title":"Biochem. Biophys. Acta"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Palmini, G., Marini, F., and Brandi, M. (2017). What is new in the miRNA world regarding osteosarcoma and chondrosarcoma?. Molecules, 22.","DOI":"10.3390\/molecules22030417"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"16121","DOI":"10.1074\/jbc.REV120.008029","article-title":"Emerging roles of the MAGE protein family in stress response pathways","volume":"295","author":"Chen","year":"2020","journal-title":"J. Biol. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/cas.14303","article-title":"ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target","volume":"111","author":"Kimura","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_40","unstructured":"(2023, September 01). Available online: www.genecards.org."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/247\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:40:42Z","timestamp":1760103642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/2\/247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["cancers16020247"],"URL":"https:\/\/doi.org\/10.3390\/cancers16020247","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}